Checkpoint Therapeutics
CKPT
Market cap $134M

2.97 USD

+0.15

5.32%

At close Oct 17, 4:00 PM EDT

After hours

2.96

-0.01

0.34%

1 day

5.32%

5 days

26.38%

1 month

17.86%

3 months

11.24%

6 months

77.84%

Year to date

35.62%

1 year

53.09%

5 years

-85.44%

About: Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Employees: 23

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

75% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 8

30% more call options, than puts

Call options by funds: $865K | Put options by funds: $664K

14% more capital invested

Capital invested by funds: $11M [Q1] → $12.6M (+$1.57M) [Q2]

13% more funds holding

Funds holding: 39 [Q1] → 44 (+5) [Q2]

7.4% less ownership

Funds ownership: 23.63% [Q1] → 16.23% (-7.4%) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$20

573%

upside

Avg. target

$20

573%

upside

High target

$20

573%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Joseph Pantginis 36% 1-year accuracy 91 / 255 met price target	573%upside $20	Buy Reiterated	16 Sept 2024
HC Wainwright & Co. Joseph Pantginis 36% 1-year accuracy 91 / 255 met price target	573%upside $20	Buy Maintained	12 Aug 2024

See Analyst Rankings

Financial journalist opinion

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024 Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 10:00 a.m. ET. The Company will also attend in-person and virtual one-on-one meetings during the conference.

Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Checkpoint Therapeutics: A Binary Bet On FDA Approval And Cosibelimab's Market Success

Checkpoint Therapeutics' Cosibelimab, an anti-PD-L1 antibody, shows promise for treating cSCC, with potential FDA approval by December 2024, making CKPT a speculative "buy." Cosibelimab's dual mechanism of action, engaging both T cells and NK cells, offers a competitive edge over other PD-L1 inhibitors, enhancing its efficacy. Despite CKPT's low cash reserves and regulatory risks, the potential market for Cosibelimab in cSCC treatment is estimated at over $1 billion in the US.

Checkpoint Therapeutics: A Binary Bet On FDA Approval And Cosibelimab's Market Success

Zacks Investment Research

What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock

Checkpoint Therapeutics (CKPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock

Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates

WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2024, and recent corporate updates.

Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates

Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review Checkpoint's resubmission of its Biologics License Application (“BLA”) for cosibelimab, its anti-programmed death ligand-1 (“PD-L1”) antibody, as a potential new treatment for adults with metastatic or locally advanced cutaneous squamous cell carcinoma (“cSCC”) who are not candidates for curative surgery or curative radiation.

Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research

YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoint Therapeutics ("Checkpoint") (Nasdaq: CKPT) have announced a collaboration to explore the combined therapeutic potential of cosibelimab, Checkpoint's anti-PD-L1 antibody with dual mechanism of action, with GC Cell's Immuncell-LC, an innovative autologous Cytokine Induced Killer (“CIK”) T cell therapy composed of cytotoxic T lymphocytes and natural killer T cells.

GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research

Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional investor for the issuance and sale of an aggregate of 5,853,659 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.05 per share of common stock (or per common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, Checkpoint will issue and sell unregistered warrants to purchase up to 5,853,659 shares of common stock. The warrants will have an exercise price of $2.05 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrant and will expire five years following the issuance date.

Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab

WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has completed the resubmission of its Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for cosibelimab, its anti-programmed death ligand-1 (“PD-L1”) antibody, as a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (“cSCC”) who are not candidates for curative surgery or curative radiation.

Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab

Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission

WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has reached alignment with the Food and Drug Administration (“FDA”) on its biologics license application (“BLA”) resubmission strategy for cosibelimab. Accordingly, Checkpoint plans to move forward with a mid-year BLA resubmission seeking the U.S. marketing approval for cosibelimab as a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (“cSCC”) who are not candidates for curative surgery or curative radiation.

Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission

See News Rankings

Charts implemented using Lightweight Charts™